

*Disclaimer :*

*The Competition DG makes the information provided by the notifying parties in section 1.2 of Form CO available to the public in order to increase transparency. This information has been prepared by the notifying parties under their sole responsibility, and its content in no way prejudices the view the Commission may take of the planned operation. Nor can the Commission be held responsible for any incorrect or misleading information contained therein.*

**COMP/M.5479 - LONZA / TEVA / JV**

## **SECTION 1.2**

### **Description of the concentration**

On April 3, 2009, the Commission received a notification concerning a proposed concentration pursuant to Article 4 of Council Regulation (EC) n° 139/2004, by which Lonza and Teva intend to create a jointly controlled joint venture that will be active in the development, production and commercialization of biosimilar products worldwide.

Lonza supplies the pharmaceutical, healthcare and life science industries with various services from research to final product manufacture. It custom-produces active pharmaceutical ingredients both chemically as well as biotechnologically, provides synthetic chemical and biotech ingredients for nutrition, hygiene, preservation, agro and personal care products, and is a leader in cell-based research, endotoxin detection and cell therapy manufacturing.

Teva is a global pharmaceutical company that specializes in the development, production and marketing of generic pharmaceutical products and proprietary pharmaceutical products, as well as (chemical) active pharmaceutical ingredients.